• AM251 as a CB1 Receptor Antagonist: Applied Workflows & Insi

  2026-07-20

  AM251 empowers neuroscientists and metabolic researchers to dissect CB1-mediated pathways with nanomolar precision. This guide distills experimental workflows, troubleshooting strategies, and data-driven tips for maximizing reproducibility and insight when leveraging AM251 from APExBIO.

• Inhibiting β-Catenin/BCL9 to Enhance Tumor Immunotherapy Res

  2026-07-20

  Feng et al. introduce a selective pharmacological approach to disrupt β-catenin/BCL9 interaction, overcoming immune checkpoint blockade resistance by modulating regulatory T cells within the tumor microenvironment. This strategy addresses a key challenge in colon and breast cancer research, promising improved synergy between targeted and immunotherapeutic interventions.

• Toremifene in Prostate Cancer Research: Protocols & Insights

  2026-07-19

  Harness Toremifene’s precision as a selective estrogen-receptor modulator for advanced prostate cancer and hormone-responsive signaling studies. This guide unpacks experimental workflows, troubleshooting strategies, and recent breakthroughs—empowering researchers to optimize reproducibility in estrogen and calcium pathway investigations.

• Docosahexaenoic Acid (DHA): Applied Workflows & Troubleshoot

  2026-07-18

  Docosahexaenoic Acid (DHA) is redefining neuroprotection and anti-inflammatory research with precise, reproducible workflows. This guide delivers actionable protocol enhancements, troubleshooting strategies, and practical application insights to maximize DHA’s translational impact in both bench and clinical models.

• Intra- and Extracellular Activity of Dicloxacillin Against M

  2026-07-17

  This article examines the reference study's systematic comparison of intra- and extracellular activity of dicloxacillin against methicillin-sensitive Staphylococcus aureus (MSSA) using both in vitro and in vivo models. The findings clarify the pharmacodynamic predictors of efficacy and establish evidence-based guidance for translational research on Gram-positive bacterial infection models.

• Deep Learning of USC Mitochondria as an Alzheimer’s Biomarke

  2026-07-17

  This study pioneers a deep learning framework to analyze mitochondrial morphology in live urine-derived stem cells (USCs) as a non-invasive biomarker for Alzheimer’s disease. By distinguishing mitochondrial dynamics in cognitively impaired individuals, the approach offers new potential for early AD detection using accessible patient samples.

• Testosterone Bounce as a Prognostic Biomarker in Degarelix T

  2026-07-16

  A recent multicenter study identifies 'testosterone bounce'—a transient rise in serum testosterone—as a significant predictor of overall and cancer-specific survival in prostate cancer patients treated with the GnRH receptor antagonist Degarelix acetate. This work refines risk stratification beyond PSA monitoring and informs future biomarker-driven therapeutic decisions.

• Enhancing Apoptosis in Pancreatic Cancer via Caspase-8/c-FLI

  2026-07-16

  The referenced study introduces a novel strategy to sensitize pancreatic cancer cells to apoptosis by pharmacologically targeting the caspase-8/c-FLIPL heterodimer and combining this with mitochondrial apoptosis induction using an MCL1 inhibitor. This combinatorial approach enhances death receptor-mediated cell death and provides a promising direction for improving therapeutic efficacy in resistant cancers.

• Neuroligin 1 Loss Drives Repetitive Behaviors via PKC in ASD

  2026-07-15

  This study reveals that loss of Neuroligin 1 in striatal D2-MSNs leads to excessive repetitive behaviors in mice, mediated by hyperactivation of the PKC pathway. The findings clarify how specific synaptic and signaling alterations contribute to autism-like behaviors and highlight PKC as a mechanistic node for future intervention.

• Targeting SCUBE3: Antibody Suppression of Cancer Progression

  2026-07-15

  This study identifies secretory protein SCUBE3 as a key driver of oncogenic signaling and immunosuppressive tumor microenvironments. The development of a neutralizing antibody against SCUBE3 demonstrates potent inhibition of tumor growth and resistance, offering a promising direction for pan-cancer therapy.

• Palmitic acid (Hexadecanoic Acid): Protocol Parameters & Wor

  2026-07-14

  Palmitic acid (SKU N2456) enables reproducible investigation of metabolic disorder pathways, protein palmitoylation, and inflammation signaling in vitro where high-purity, non-aqueous fatty acid delivery is essential. It is not suitable for protocols requiring aqueous solubility or long-term solution stability.

• NHS-Biotin: Precision Biotinylation for Multimeric Protein W

  2026-07-14

  NHS-Biotin (N-hydroxysuccinimido biotin) delivers exceptional versatility for biotinylating antibodies, nanobodies, and proteins, enabling robust labeling and purification. Discover step-by-step protocols, troubleshooting insights, and how the latest peptidisc-assisted clustering expands biotinylation to next-generation protein engineering.

• METTL16-SENP3-LTF Axis Drives Ferroptosis Resistance in HCC

  2026-07-13

  Wang et al. uncover a novel METTL16-SENP3-LTF signaling axis that confers ferroptosis resistance and promotes tumorigenesis in hepatocellular carcinoma (HCC). This mechanistic insight highlights iron metabolic regulation as a therapeutic vulnerability, with implications for targeting ferroptosis in resistant liver cancers.

• Dacomitinib (PF-00299804): Reliable Pan-HER Tool for Cancer

  2026-07-13

  This article addresses real-world laboratory challenges in cancer research, focusing on reproducibility and data quality in cell-based assays using Dacomitinib (PF-00299804), SKU A8319. We explore evidence-based solutions for apoptosis induction, cell cycle arrest, and resistance modeling, guiding researchers on protocol optimization and trusted sourcing.

• Talabostat Mesylate (PT-100): Cutting-Edge Protocols in Tumo

  2026-07-12

  Talabostat mesylate (PT-100) unlocks new experimental frontiers in tumor microenvironment modulation and T cell inflammasome research. This guide details advanced workflows, troubleshooting, and protocol enhancements, directly informed by recent breakthroughs in CARD8 inflammasome activation and APExBIO’s trusted reagent quality.

16356 records 1/1091 page Next 12345 下5页 Last page